Dr. Charles Perou on Molecular Differences in Lobular Breast Cancer
Perou says this research also found three expression subtypes within lobular breast cancer, one of which showed a proliferative phenotype and portended a slightly worse prognosis.
Charles Perou, PhD, professor of Genetics, Pathology & Laboratory Medicine, Lineberger Comprehensive Cancer Center, UNC School of Medicine, discusses a recent paper published from The Cancer Genome Atlas focusing on lobular breast cancer as a distinct molecular disease. Perou says this research also found three expression subtypes within lobular breast cancer, one of which showed a proliferative phenotype and portended a slightly worse prognosis.
He adds that the other two subtypes of lobular breast cancer were defined by unique features of the microenvironment. In one of the two subtypes, Perou says there appeared to be immune cell infiltrates, while in the other subtype there appeared to be fibroblasts and other types of stromal cell infiltrates.
Managing HER2+ Early Breast Cancer: Insights and Future Horizons
November 28th 2023Sandra M. Swain, MD, FACP, FASCO, discusses the potential role for HER2-directed TKIs for the treatment of patients with early-stage HER2+ breast cancer and shares insights about emerging data that could impact the future treatment landscape.
Read More
Navigating HER2+ Early Breast Cancer: Insights Into the Current Treatment Landscape
November 28th 2023In this companion article, Sandra M. Swain, MD, FACP, FASCO, provides insights into effective management of patients with early-stage HER2+ breast cancer and reviews recent data in the evolving treatment landscape.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
ctDNA Helps Identify Targets in HR+, HER2- Metastatic Breast Cancer
November 22nd 2023In the first article of a 2-part series, Hope S. Rugo, MD, FASCO, discusses how the use of circulating tumor DNA can aid in allowing next generation sequencing to better identify targets for patients with hormone receptor positive metastatic breast cancer.
Read More
